WO2001022969A3 - Vasopressin agonist formulation and process - Google Patents
Vasopressin agonist formulation and process Download PDFInfo
- Publication number
- WO2001022969A3 WO2001022969A3 PCT/US2000/026380 US0026380W WO0122969A3 WO 2001022969 A3 WO2001022969 A3 WO 2001022969A3 US 0026380 W US0026380 W US 0026380W WO 0122969 A3 WO0122969 A3 WO 0122969A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- vasopressin agonist
- agonist formulation
- formulations
- vasopressin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001526180A JP2003510280A (en) | 1999-09-27 | 2000-09-26 | Vasopressin agonist prescription and manufacturing method |
AU76152/00A AU7615200A (en) | 1999-09-27 | 2000-09-26 | Vasopressin agonist formulation and process |
EP00965432A EP1216045A2 (en) | 1999-09-27 | 2000-09-26 | Vasopressin agonist formulation and process |
CA002385971A CA2385971A1 (en) | 1999-09-27 | 2000-09-26 | Vasopressin agonist formulation and process |
MXPA02003191A MXPA02003191A (en) | 1999-09-27 | 2000-09-26 | Vasopressin agonist formulation and process. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40616599A | 1999-09-27 | 1999-09-27 | |
US09/406,165 | 1999-09-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001022969A2 WO2001022969A2 (en) | 2001-04-05 |
WO2001022969A3 true WO2001022969A3 (en) | 2001-12-20 |
Family
ID=23606805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/026380 WO2001022969A2 (en) | 1999-09-27 | 2000-09-26 | Vasopressin agonist formulation and process |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1216045A2 (en) |
JP (1) | JP2003510280A (en) |
CN (1) | CN1391476A (en) |
AU (1) | AU7615200A (en) |
CA (1) | CA2385971A1 (en) |
MX (1) | MXPA02003191A (en) |
WO (1) | WO2001022969A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138393B2 (en) * | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
EP1615698B1 (en) * | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
AR094929A1 (en) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2 |
WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521173A (en) * | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
WO1996022293A1 (en) * | 1995-01-17 | 1996-07-25 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
WO1999006409A1 (en) * | 1997-07-30 | 1999-02-11 | American Home Products Corporation | Tricyclic vasopressin agonists |
US6090803A (en) * | 1998-07-24 | 2000-07-18 | American Home Products Corporation | Tricyclic vasopressin agonists |
WO2000046227A1 (en) * | 1999-02-04 | 2000-08-10 | American Home Products Corporation | Thienylbenzoylbenzazepines as vasopressin agonists |
-
2000
- 2000-09-26 CN CN00816009A patent/CN1391476A/en active Pending
- 2000-09-26 MX MXPA02003191A patent/MXPA02003191A/en unknown
- 2000-09-26 WO PCT/US2000/026380 patent/WO2001022969A2/en not_active Application Discontinuation
- 2000-09-26 JP JP2001526180A patent/JP2003510280A/en active Pending
- 2000-09-26 CA CA002385971A patent/CA2385971A1/en not_active Abandoned
- 2000-09-26 EP EP00965432A patent/EP1216045A2/en not_active Withdrawn
- 2000-09-26 AU AU76152/00A patent/AU7615200A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521173A (en) * | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
WO1996022293A1 (en) * | 1995-01-17 | 1996-07-25 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
WO1999006409A1 (en) * | 1997-07-30 | 1999-02-11 | American Home Products Corporation | Tricyclic vasopressin agonists |
US6090803A (en) * | 1998-07-24 | 2000-07-18 | American Home Products Corporation | Tricyclic vasopressin agonists |
WO2000046227A1 (en) * | 1999-02-04 | 2000-08-10 | American Home Products Corporation | Thienylbenzoylbenzazepines as vasopressin agonists |
Non-Patent Citations (1)
Title |
---|
See also references of EP1216045A2 * |
Also Published As
Publication number | Publication date |
---|---|
EP1216045A2 (en) | 2002-06-26 |
AU7615200A (en) | 2001-04-30 |
CA2385971A1 (en) | 2001-04-05 |
WO2001022969A2 (en) | 2001-04-05 |
JP2003510280A (en) | 2003-03-18 |
MXPA02003191A (en) | 2002-09-30 |
CN1391476A (en) | 2003-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001032596A8 (en) | Phenoxy carboxylic acid compounds and compositions for delivering active agents | |
WO1997012583A3 (en) | Stable compositions containing n-propargyl-1-aminoindan | |
CA2158630A1 (en) | Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability | |
CA2339765A1 (en) | Compounds and compositions for delivering active agents | |
AU3038197A (en) | Aerosol formulations | |
CA2448035A1 (en) | New pharmaceutical composition | |
WO2003002136A3 (en) | Stable formulation of modified glp-1 | |
CA2411754A1 (en) | 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents | |
WO2001005388A3 (en) | Use of a fatty derivative for the treatment of external secretiondisorders | |
WO2002094210A3 (en) | Cosmetic agents | |
AU2093101A (en) | Compositions for efficient release of active ingredients | |
CA2304568A1 (en) | Olanzapine pamoate formulations | |
CA2271196A1 (en) | Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability | |
WO2001005355A3 (en) | Formulations for il-11 | |
CA2294913A1 (en) | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative | |
CA2294033A1 (en) | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation | |
WO2001095856A3 (en) | Urea derivative useful as an anti-cancer agent and process for preparing same | |
HUP0204513A3 (en) | Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients | |
WO2004060347A3 (en) | Pharmaceutical propylene glycol solvate compositions | |
WO2002015959A3 (en) | Compounds and compositions for delivering active agents | |
WO2001093816A3 (en) | Stabilized compositions containing oxygen-labile active agents | |
AU2001227030A1 (en) | Pharmaceutical composition for controlled release of an active ingredient | |
WO2001022969A3 (en) | Vasopressin agonist formulation and process | |
AU2001215584A1 (en) | A pharmaceutical composition having chlorogenic acid as active component for preventing or treating the declining of male reproduction capability | |
UA74388C2 (en) | Pharmaceutical compositions of tysoxanide and nitasoxanide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000965432 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 526180 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2385971 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/003191 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008160090 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000965432 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000965432 Country of ref document: EP |